Korea Investment CORP Buys Shares of 91,843 Illumina, Inc. $ILMN

Posted by Brenda Bartman on Aug 24th, 2026

Korea Investment CORP bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 91,843 shares of the life sciences company’s stock, valued at approximately $16,149,000.

Other large investors also recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of Illumina in the 2nd quarter worth about $726,000. Rakuten Securities Inc. bought a new stake in shares of Illumina during the 2nd quarter valued at about $33,000. Ieq Capital LLC bought a new stake in shares of Illumina during the 2nd quarter valued at about $47,111,000. Callan Family Office LLC acquired a new stake in Illumina during the second quarter worth about $1,803,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in Illumina during the second quarter worth about $32,000. 89.42% of the stock is currently owned by institutional investors.

Insider Transactions at Illumina

In related news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 2,095,958 shares of company stock worth $401,720,974. Company insiders own 2.90% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

Illumina stock opened at $219.40 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The firm has a 50-day moving average price of $188.01 and a two-hundred day moving average price of $152.52. The firm has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $220.43.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research reports. Citigroup lifted their target price on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Royal Bank Of Canada increased their price target on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Finally, Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $188.40.

Get Our Latest Research Report on Illumina

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.